Dr. Rohini Rajnarayanan, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 36065 Santa Fe Ave, Fort Cavazos, TX 76544 Phone: 336-898-1246 |
News Archive
IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has raised $8 million through a note offering to existing shareholders. The new funding will be used to further develop its pipeline of cancer vaccine candidates, including its lead product, IRX-2. IRX Therapeutics has now raised a total of more than $80 million in private financing.
Vaxonco Inc., a Korean company specializing in peptide-based vaccines and Ichor Medical Systems (Ichor), whose advanced TriGridâ„¢ Delivery System (TriGridâ„¢) is being tested worldwide for its ability to enhance delivery of DNA drugs and vaccines, announced today the initiation of a Phase I clinical trial to evaluate a novel DNA-based polyepitope vaccine against malaria.
Rush University Medical Center has received a three-year, $2.45 million grant from the U.S. Health Resources and Services Administration to support quality care for older Americans. Rush is one of only 44 health and education institutions in the country that the HRSA chose to become a Geriatrics Workforce Enhancement Program, which supports training and education that leads to better care for older adults.
When it comes to the prostate cancer, the disease known as the "silent killer" because it often exhibits no symptoms, to be forewarned is to be forearmed. It is the second leading cancer killer in men, just behind lung cancer. Every year, more than 218,000 men are diagnosed with prostate cancer in the United States, claiming about 28,000 lives.
› Verified 6 days ago